From the Journals

More evidence links increased BMI to higher multiple myeloma risk


 

FROM BRITISH JOURNAL OF CANCER

“Our findings support the growing body of literature demonstrating that a high BMI both early and later in adulthood is associated with the risk of MM, and suggest that maintaining a healthy body weight throughout life may be an important component to a much-needed MM prevention strategy,” wrote Dr. Marinac, who also is affiliated with the Harvard T.H. Chan School of Public Health, also in Boston.

“Further larger-scale studies aimed at clarifying the influence of obesity timing and duration and at directly evaluating the role of weight loss, ideally conducted in diverse prospective study populations and in [monoclonal gammopathy of undetermined significance] patients, will be important for elaborating the role of weight maintenance in MM prevention and for identifying high risk subgroups of patients that may benefit from weight loss.”

None of the researchers had competing financial interests to disclose.

SOURCE: Marinac CR et al. Br J Cancer. 2018 Mar 12. doi: 10.1038/s41416-018-0010-4.

Pages

Recommended Reading

Denosumab on par with zoledronic acid for multiple myeloma bone disease
MDedge Hematology and Oncology
Export protein inhibitor shows activity against refractory myeloma
MDedge Hematology and Oncology
High efficacy, no safety signals for herpes zoster vaccine post-HSCT
MDedge Hematology and Oncology
In myeloma, third ASCT is a viable option
MDedge Hematology and Oncology
Researchers question validity of NCCN guidelines
MDedge Hematology and Oncology
Drug approved to treat newly diagnosed MM in China
MDedge Hematology and Oncology
CHMP supports approval of denosumab in MM
MDedge Hematology and Oncology
Regimen deemed ‘safe and feasible’ in MM
MDedge Hematology and Oncology
Study reveals lack of sexual aids for cancer survivors
MDedge Hematology and Oncology
Drug receives orphan designation for MM
MDedge Hematology and Oncology